Paratek is focused on the discovery, development, and commercialization of medicines designed to save lives and alleviate suffering.

 

Effective October 30, 2014, Transcept Pharmaceuticals, Inc. and Paratek Pharmaceuticals, Inc. closed a merger that resulted in a change in the name of Transcept Pharmaceuticals to Paratek Pharmaceuticals. The ticker symbol for Transcept has also changed from 'TSPT' to 'PRTK'.

Paratek is a pharmaceuticals company focused on the discovery, development, and commercialization of medicines designed to save lives and alleviate suffering. Our lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern.

Latest News

Paratek to present at Future Leaders in the Biotech Industry Conference on March 20th (webcast link)

Special Cash Dividend

On October 14, 2014 Transcept Pharmaceuticals declared a special cash dividend, in connection with its merger with Paratek Pharmaceuticals.